Business Description
Arcellx Inc
NAICS : 325412
SIC : 2834
25 West Watkins Mill Road, Suite A, Gaithersburg, MD, USA, 20878
Description
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 40.45 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.32 | |||||
| 9-Day RSI | 48.09 | |||||
| 14-Day RSI | 51.74 | |||||
| 6-1 Month Momentum % | 13.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.14 | |||||
| Quick Ratio | 13.14 | |||||
| Cash Ratio | 12.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -30.78 | |||||
| ROIC % | -294.74 | |||||
| ROC (Joel Greenblatt) % | -523.07 | |||||
| ROCE % | -33.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.14 | |||||
| Price-to-Tangible-Book | 3.15 | |||||
| EV-to-EBIT | -12.21 | |||||
| EV-to-EBITDA | -12.38 | |||||
| EV-to-Forward-EBITDA | -4.92 | |||||
| EV-to-FCF | -11.15 | |||||
| Price-to-Net-Current-Asset-Value | 3.51 | |||||
| Price-to-Net-Cash | 3.69 | |||||
| Earnings Yield (Greenblatt) % | -8.19 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ACLX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.867 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 51.74 | ||
| 14-Day ATR ($) | 1.736909 | ||
| 20-Day SMA ($) | 19.801 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 6.035 - 26.91 | ||
| Shares Outstanding (Mil) | 43.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcellx Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||